# How does Thymosin Alpha-1 improve immune function in aging liver tissues?

Canonical source: https://retacompare.com/research/how-does-thymosin-alpha-1-improve-immune-function-in-aging-liver-tissues

Peptide Longevity Q&A · 2026-03-26


    Research indicates that Thymosin Alpha-1, when combined with IL-15, reduces senescent CD8(+) T cells in the liver, enhancing immune function and antitumor immunity in hepatocellular carcinoma. This combination therapy rejuvenates the T cell pool, potentially impacting aging-related immune decline.

 What the research shows

The study investigated the effects of Thymosin Alpha-1 (Tα1) and interleukin-15 (IL-15) on senescent CD8(+) T cells in an orthotopic hepatocellular carcinoma (HCC) model using aged C57BL/6 mice. The mice were divided into groups receiving saline, IL-15, Tα1, or a combination of both therapies. Tumor progression was assessed through bioluminescence imaging, survival analysis, and histopathological examination. The researchers analyzed the phenotype and function of hepatic CD8(+) T cells using multicolor flow cytometry, immunofluorescence, transcriptomic sequencing, and Western blotting. Additionally, primary human CD8(+) T cells were co-cultured with Huh7 hepatoma cells for in vitro validation.

 Why it matters for longevity

This research highlights the potential of Thymosin Alpha-1 in addressing immunosenescence, a significant factor in aging and age-related diseases, including cancer. By reducing the proportion of senescent CD8(+) T cells and enhancing the proliferation and activation of effector T cells, Tα1 may help restore immune function in older populations. The study suggests that therapies targeting immune rejuvenation could play a crucial role in extending healthspan and improving outcomes in age-related conditions.

 Key findings at a glance

The combination of IL-15 and Thymosin Alpha-1 significantly suppressed tumor growth in a mouse model of HCC.

It reduced the proportion of senescent CD8(+) T cells while increasing activated effector T cell populations.

The therapy enhanced the proliferative capacity of CD8(+) T cells and upregulated cytotoxic mediators.

It attenuated overactivated PI3K/AKT signaling pathways in hepatic CD8(+) T cells.

In vitro studies confirmed that pathway suppression is a key mechanism of the combination therapy.

 How Thymosin Alpha-1 works (background)

Thymosin Alpha-1 is a peptide that plays a role in immune system regulation. It is known for its ability to enhance T cell function and promote thymic rejuvenation, which is particularly important in aging populations where T cell output diminishes. By restoring the T cell pool and enhancing the activation of CD8(+) T cells, Tα1 may counteract the effects of immunosenescence. The study demonstrated that Tα1, in combination with IL-15, not only revitalizes T cell populations but also suppresses overactive signaling pathways, which are often implicated in tumor progression and immune dysfunction.

 Safety, caveats, and what we don't yet know

While the findings are promising, they are based on preclinical models, and further research is necessary to confirm the effects of Thymosin Alpha-1 in human populations. The study primarily focused on aged mice, and the extrapolation of these results to humans requires caution. Additionally, the long-term safety and efficacy of Thymosin Alpha-1, particularly in diverse populations and in conjunction with other therapies, remain to be fully explored.

 Bottom line

Thymosin Alpha-1 shows potential in improving immune function by reducing senescent CD8(+) T cells and enhancing antitumor immunity, which may have implications for aging-related immune decline.

 Related questions

 Can Thymosin Alpha-1 enhance immune response in older adults?

Research suggests that Thymosin Alpha-1 may enhance immune response by rejuvenating T cell populations, potentially improving outcomes in older adults facing immune decline.

 What role does IL-15 play in immune health?

IL-15 is crucial for T cell survival and proliferation. It helps rescue senescent T cells, enhancing their functionality and potentially improving immune health in aging populations.

 How does immunosenescence affect cancer progression?

Immunosenescence leads to a decline in T cell function, which can impede the body's ability to combat cancer. Targeting this decline with therapies like Thymosin Alpha-1 may improve antitumor immunity.

 Source: PubMed · J Gastroenterol Hepatol · published 2026-03-26.

## Sources

- PubMed · J Gastroenterol Hepatol: https://pubmed.ncbi.nlm.nih.gov/41883056/